Clinical Trial Update: An Expanded Access Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Negative Chronic Hepatitis B [Phase 4]

View source ↗

Summary

Expanded-access study of Pegasys (peginterferon alfa-2a) in HBeAg-negative chronic hepatitis B completed the Phase 4 protocol, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis B, Chronic | Phase 4 | Status: COMPLETED | Results posted: 2016-07-22